دورية أكاديمية
أعرض في EDS

Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants.

التفاصيل البيبلوغرافية
العنوان: Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants.
المؤلفون: Walters AA; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK., Ali A; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK., Wang JT; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK., Al-Jamal KT; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK. Khuloud.al-jamal@kcl.ac.uk.
المصدر: Drug delivery and translational research [Drug Deliv Transl Res] 2023 Jul; Vol. 13 (7), pp. 2032-2040. Date of Electronic Publication: 2022 Nov 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York : Springer
مواضيع طبية MeSH: Adjuvants, Immunologic* , Neoplasms*, Mice ; Animals ; Antibodies
مستخلص: In situ vaccination with immunostimulatory compounds is a demonstrated means to treat tumors preclinically. While these therapeutic effects have been attributed to the actions of T cells or innate immune activation, characterisation of the humoral immune response is seldom performed. This study aims to identify whether the injection of immunoadjuvants, Addavax (Adda) and cytosine-phosphorothioate-guanine oligodeoxynucleotide (CpG), intratumorally can influence the antibody response. Specifically, whether intratumoral injection of immunoadjuvants can alter the tumor-specific antibody target, titre and isotype. Following this, the study aimed to investigate whether serum obtained from in situ vaccinated mice could neutralise circulating tumor cells. Serum was obtained from mice bearing B16F10-OVA-Luc-GFP tumors treated with immunoadjuvants. Antibody targets' titre and isotype were assessed by indirect ELISA. The ability of serum to neutralise circulating cancer cells was evaluated in a B16F10 pseudo-metastatic model. It was observed that tumor-bearing mice mount a specific anti-tumor antibody response. Antibody titre and target were unaffected by in situ vaccination with immunoadjuvants; however, a higher amount of IgG2c was produced in mice receiving Adda plus CpG. Serum from in situ vaccinated mice was unable to neutralise circulating B16F10 cells. Thus, this study has demonstrated that anti-tumor antibody isotype may be modified using in situ vaccination; however, this alone is not sufficient to neutralise circulating cancer cells.
(© 2022. The Author(s).)
References: Adv Mater. 2021 Aug;33(31):e2100628. (PMID: 34118167)
Int Immunopharmacol. 2012 Aug;13(4):408-16. (PMID: 22595192)
J Transl Med. 2012 Jan 05;10:4. (PMID: 22221900)
Cancer Immunol Immunother. 2016 Aug;65(8):885-96. (PMID: 27222052)
Lancet Oncol. 2002 Mar;3(3):137-44. (PMID: 11902499)
Science. 2005 Dec 2;310(5753):1510-2. (PMID: 16322460)
Cancer Res. 2016 Dec 1;76(23):6864-6876. (PMID: 27634753)
Cancer Res. 1989 Jul 15;49(14):3722-8. (PMID: 2736512)
Mol Oncol. 2015 Dec;9(10):1966-81. (PMID: 26632446)
Oncogene. 2007 May 28;26(25):3637-43. (PMID: 17530017)
Oncol Rep. 2015 Sep;34(3):1106-14. (PMID: 26133558)
J Immunol. 2012 Feb 15;188(4):1592-9. (PMID: 22231700)
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1119-1128. (PMID: 31888983)
J Immunol. 2007 Feb 15;178(4):2415-20. (PMID: 17277148)
Tissue Antigens. 2007 Jul;70(1):1-11. (PMID: 17559575)
Immunity. 2020 Jan 14;52(1):17-35. (PMID: 31940268)
PLoS One. 2011 Apr 29;6(4):e19330. (PMID: 21559411)
Cancer Res. 2006 Aug 1;66(15):7741-7. (PMID: 16885377)
Macromol Biosci. 2021 Feb;21(2):e2000207. (PMID: 33107202)
Cancer Cell. 2010 Feb 17;17(2):121-34. (PMID: 20138013)
J Exp Med. 1999 Sep 6;190(5):617-27. (PMID: 10477547)
Br Med J. 1969 Sep 6;3(5670):547-52. (PMID: 4896110)
J Nanobiotechnology. 2022 Mar 27;20(1):160. (PMID: 35351156)
Front Immunol. 2020 Jul 24;11:1610. (PMID: 32849544)
J Immunol. 2009 Jul 15;183(2):1005-12. (PMID: 19542370)
Oncoimmunology. 2017 Mar 3;6(4):e1294296. (PMID: 28507802)
Blood. 2003 Jun 1;101(11):4500-4. (PMID: 12560217)
Hum Vaccin Immunother. 2015;11(8):1901-9. (PMID: 26055074)
Neoplasia. 1999 Nov;1(5):453-60. (PMID: 10933061)
J Immunol. 2010 Apr 1;184(7):4006-16. (PMID: 20194720)
Biomaterials. 2016 Oct;104:310-22. (PMID: 27475727)
Int J Cancer. 2003 Jan 1;103(1):97-100. (PMID: 12455059)
Nature. 2015 May 7;521(7550):99-104. (PMID: 25924063)
J Exp Med. 1997 Nov 17;186(10):1623-31. (PMID: 9362523)
Immunology. 2001 Apr;102(4):486-97. (PMID: 11328383)
J Immunol. 1988 Feb 15;140(4):1022-7. (PMID: 3125247)
Hum Vaccin Immunother. 2018;14(12):3041-3045. (PMID: 30015572)
Nat Med. 2016 Dec;22(12):1402-1410. (PMID: 27775706)
Int J Urol. 2004 Dec;11(12):1070-7. (PMID: 15663677)
معلومات مُعتمدة: WT103913 United Kingdom WT_ Wellcome Trust; United Kingdom CRUK_ Cancer Research UK
فهرسة مساهمة: Keywords: Antibody neutralisation; B16F10; CpG; Immunoadjuvants; In situ vaccination; Isotype
المشرفين على المادة: 0 (Adjuvants, Immunologic)
0 (Antibodies)
تواريخ الأحداث: Date Created: 20221123 Date Completed: 20230605 Latest Revision: 20231116
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10238356
DOI: 10.1007/s13346-022-01258-8
PMID: 36417163
قاعدة البيانات: MEDLINE
الوصف
تدمد:2190-3948
DOI:10.1007/s13346-022-01258-8